Physician profile
David Chim
NPI 1346306388
$1,269.11
in general payments reported to CMS, 2019-2025
18 companies · $565 in 2025
The $565 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $199 · 2024: $505 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,269.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $152.21 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $129.20 | 2023-2024 | Farxiga, Breztri |
| Verona Pharma, INC. | $123.92 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $114.10 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.69 | 2023-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $85.82 | 2025 | Strensiq |
| Novo Nordisk INC | $80.77 | 2024-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $76.68 | 2025 | |
| Exact Sciences Corporation | $71.71 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $60.24 | 2024 | |
| Sanofi-Aventis U.S. LLC | $52.13 | 2024 | |
| Abbvie INC. | $44.04 | 2023-2024 | Ubrelvy |
| Kowa Pharmaceuticals America, INC. | $37.63 | 2024-2025 | Zoryve |
| Abbott Laboratories | $32.37 | 2025 | Id Now Instrument |
| Sumitomo Pharma America, INC. | $29.44 | 2023 | Gemtesa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $27.80 | 2025 | Korlym |
| Gilead Sciences, INC. | $19.73 | 2025 | |
| Amgen INC. | $18.63 | 2024 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.